glp-1 dementia study drugs failed to slow Alzheimer's in two big clinical trials GLP-1R agonists protect against Alzheimer's
Description
J Addiction Med
cell Sci
Pfizer is building a trial that can answer, within a year or two, whether monthly is a clinically defensible default schedule or a niche convenience option
Built for GLP-1 so you always know where you stand and what to do next
The company reported favorable Phase 3 results last month, saying that it is on track to submit the drug for regulatory approval by year-end
